{"entity":{"id":"nct03774732","kind":"trial","name":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","aka":["NIRVANA-LUNG"],"tldr":"A phase 3 trial of pembrolizumab in lung cancer, run by UNICANCER, active but no longer recruiting.","summary":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT03774732 by UNICANCER, with a registry enrolment figure of 327 participants, started 2018-01-24 and due to reach its primary completion in 2026-12-22. Interventions recorded: Radiotherapy; Pembrolizumab; Chemotherapy. Conditions listed: Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4. Primary outcome: 1-year Overall Survival. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed advanced (stage IIIB/IIIC/IV), squamous or non-squamous NSCLC\". Sites: France, Monaco. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT03774732","url":"https://clinicaltrials.gov/study/NCT03774732"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["pembrolizumab"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03774732","phase":"3","setting":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","sponsor":"UNICANCER","enrolled":327,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03774732/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}